乌帕替尼治疗炎症性肠病的长期安全性:2/3期研究整合分析
该整合分析基于6项UC/CD临床试验,评估乌帕替尼(UPA)长期安全性。维持/长期扩展期UPA累计暴露5149.3患者年,不良事件发生率与安慰剂相当,导致停药及严重不良事件较低,总体耐受性良好。
要点
- UPA维持/长期扩展期累计暴露5149.3患者年,中位治疗时长UPA15为58.1周、UPA30为130.9周。
- 诱导和维持期UPA与安慰剂不良事件发生率相当,导致停药及严重不良事件UPA更低。
- 带状疱疹、中性粒细胞减少、淋巴细胞减少、CPK升高、肝病和COVID-19在UPA组较高。
核心结论
- 长期来看UPA总体耐受性良好,本整合分析支持其有利的安全性特征及IBD治疗决策。
研究设计与样本
- 整合6项UC/CD临床试验的安全性数据,包括诱导期(安慰剂n=725,UPA45 n=1393)和维持/长期扩展期(安慰剂n=468,UPA15 n=471,UPA30 n=480)。
主要发现
- 维持/长期扩展期UPA累计暴露5149.3患者年(n=1910);UPA45诱导中位治疗8.7周,UPA15和UPA30维持/长期扩展中位治疗分别为58.1周和130.9周。
- 诱导和维持/长期扩展期,UPA与安慰剂不良事件发生率相当,导致停药的不良事件及严重或重度不良事件UPA更低。
- 维持/长期扩展期,静脉血栓栓塞事件率UPA15/30 vs 安慰剂为0.3/0.4 vs 0 E/100 PY,胃肠穿孔为0.4/<0.1 vs 0.8 E/100 PY,导致死亡的不良事件为0.2/<0.1 vs 0 E/100 PY。
- 带状疱疹、中性粒细胞减少、淋巴细胞减少、肌酸磷酸激酶升高、肝脏疾病和COVID-19在UPA各组高于安慰剂;COVID-19和带状疱疹是维持期最常见不良事件之一。
临床怎么用
- 长期使用UPA治疗UC或CD时,应关注带状疱疹、中性粒细胞减少、淋巴细胞减少、肌酸磷酸激酶升高、肝脏疾病和COVID-19等不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Upadacitinib (UPA) is an oral, reversible Janus kinase inhibitor approved for the treatment of ulcerative colitis (UC) and Crohn's disease (CD). We assessed the long-term safety of UPA in both inflammatory bowel disease (IBD) entities. METHODS: Safety from 6 UC/CD trials assessed UPA 45 mg (UPA45) once daily (QD) induction, UPA 15 mg and 30 mg (UPA 15/30 QD) maintenance/long-term extension (LTE) doses, and rescue therapy (UPA30 QD). Adverse events (AEs) were reported as events per 100 patient-years (E/100 PY). RESULTS: Overall, 2118 patients received placebo (PBO; n = 725) or UPA45 (n = 1393) induction; 1419 received PBO (n = 468), UPA15 (n = 471), or UPA30 (n = 480) maintenance/LTE. During maintenance/LTE, UPA cumulative exposure was 5149.3 patient-years (n = 1910). Median treatment duration was 8.7 weeks (interquartile range [IQR], 8.0-12.0 weeks) for UPA45 induction; median maintenance/LTE treatment duration was 58.1 weeks (IQR, 30.4-164.0 weeks) for UPA15, and 130.9 weeks (IQR, 39.4-175.1 weeks) for UPA30. AE incidence was comparable between UPA and PBO during induction and maintenance/LTE; AEs leading to study drug discontinuation and serious or severe AEs were lower with UPA. During maintenance/LTE, rates (UPA15/30 vs PBO) of venous thromboembolic events (0.3/0.4 vs 0 E/100 PY), gastrointestinal perforations (0.4/<0.1 vs 0.8 E/100 PY), and AEs leading to death (0.2/<0.1 vs 0 E/100 PY) were low. Herpes zoster, neutropenia, lymphopenia, creatine phosphokinase elevation, hepatic disorder, and COVID-19 were higher across UPA groups vs PBO; COVID-19 and herpes zoster were among the most common AEs during maintenance. CONCLUSIONS: Long-term, UPA was generally well-tolerated. This integrated analysis supports the favorable safety profile of UPA and treatment decisions for patients with IBD. CLINICALTRIALS: gov, Numbers: NCT02819635, NCT03653026, NCT03006068, NCT03345836, NCT03345849, and NCT03345823.
引用
- Panaccione R, Panés J, Peyrin-Biroulet L, et al. Long-Term Safety of Upadacitinib in Patients With Inflammatory Bowel Disease: Integrated Analysis of Phase 2/3 Studies. Clin Gastroenterol Hepatol. 2026. PMID: 41763462. doi:10.1016/j.cgh.2026.02.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。